Antisense And Rnai Therapeutics Market: Market Size & Forecast 2026

Antisense oligonucleotides (ASOs) and RNA interference (RNAi) therapeutics work by binding to messenger RNA or other RNA targets to selectively silence disease-driving genes. The market includes both approved products and a deep clinical pipeline spanning cardiometabolic disease, rare genetic conditions, neurological disorders, and oncology. Commercial leaders such as Spinraza, Tegsedi, Waylivra, Onpattro, Givlaari, Oxlumo, Leqvio, and Amvuttra have demonstrated that RNA-targeted drugs can achieve blockbuster-scale sales and durable franchises.

• •Global market size: ~$4.19 billion in 2025
• •Compound annual growth rate: approximately 16.5%
• •Strong late-stage pipeline with multiple Phase 3 candidates in oncology, neurology, and cardiometabolic disease

Three structural forces are sustaining the market's rapid expansion. First, the rising prevalence of rare genetic disorders and chronic liver, cardiovascular, and neurodegenerative diseases is generating demand for treatments that address previously undruggable targets. Second, breakthroughs in conjugate chemistry, GalNAc liver delivery, and lipid nanoparticle platforms have dramatically improved potency and tolerability, enabling subcutaneous dosing and chronic use. Third, large pharmaceutical companies continue to validate the modality through licensing deals and acquisitions, with cardiovascular programs such as Leqvio establishing that RNAi can deliver durable, infrequent dosing in high-prevalence settings.

• •Expansion of GalNAc-mediated liver-targeted RNAi platforms
• •Growing number of FDA and EMA approvals since 2018 for ASO and siRNA drugs
• •Major pharma partnerships and licensing deals with biotech innovators

The market is commonly segmented by molecule type into antisense oligonucleotides and small interfering RNA (siRNA) products, with RNAi capturing a growing share following recent approvals. By application, oncology, rare genetic disease, cardiometabolic disease, and neurology represent the leading therapeutic areas. North America holds the largest regional share due to a concentrated biotech ecosystem, strong reimbursement frameworks, and early FDA approvals, while Asia-Pacific is the fastest-growing region supported by expanding clinical trial activity and rising healthcare investment in China, Japan, and South Korea.

• •RNAi is gaining share relative to ASOs following recent cardiovascular and liver-directed approvals
• •North America leads in revenue; Asia-Pacific is the fastest-growing region
• •Oncology and cardiometabolic applications are key expansion areas

What are the recent trends and outlook?

The market is expected to remain on a high-growth trajectory as additional RNAi and ASO approvals diversify beyond liver-directed and rare-disease applications into central nervous system and oncology indications. Delivery technology improvements and combination therapies are likely to broaden the addressable patient population, while pricing pressure and reimbursement scrutiny could become more pronounced in cardiometabolic indications given large eligible populations. Overall, the modality is transitioning from a niche rare-disease category into a mainstream therapeutic class within the biopharmaceutical industry.

• •Pipeline expansion into CNS and oncology indications
• •Increasing focus on extrahepatic delivery beyond liver-targeted GalNAc
• •Long-term outlook remains strong, with sustained double-digit annual growth expected